DNMT3A and acute myeloid leukemia: Concurrent DNMT3A and FLT3-ITD mutation in AML patients is related to poorer OS and worse outcomes after chemotherapy compared to single mutated FLT3-ITD or DNMT3A AML patients [190–194] The effectiveness of chemotherapy is also decreased in DNMT3A/FLT3-ITD-mutated patient group [191].